Table 1 Chemotherapy in addition to supportive care in advanced NSCLC: main results of the meta-analysis performed on individual patient data from 16 randomised controlled trials [2]
Arm
ChemotherapySupportive care
Patients n13991315
Deaths n12931240
Hazard ratio0.7795% CI : 0.71–0.83 P<0.0001
1-yr survival29%20%
Median survival6 months4.5 months